Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

SELL
$14.5 - $38.0 $493 - $1,292
-34 Reduced 33.01%
69 $2,000
Q3 2023

Oct 25, 2023

BUY
$15.75 - $26.31 $1,622 - $2,709
103 New
103 $1,000
Q4 2022

Jan 24, 2023

BUY
$20.18 - $33.33 $665 - $1,099
33 Added 80.49%
74 $0
Q3 2022

Nov 10, 2022

SELL
$11.58 - $24.73 $1,204 - $2,571
-104 Reduced 71.72%
41 $1,000
Q2 2022

Aug 01, 2022

BUY
$8.52 - $25.26 $570 - $1,692
67 Added 85.9%
145 $2,000
Q1 2022

Apr 21, 2022

BUY
$19.89 - $43.18 $1,551 - $3,368
78 New
78 $2,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.